close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by VALNEVA

< Previous 1 2 3 4 Next >
Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine
From VALNEVA
Via GlobeNewswire
Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer
From VALNEVA
Via GlobeNewswire
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine
From VALNEVA
Via GlobeNewswire
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
From VALNEVA
Via GlobeNewswire
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
From VALNEVA
Via GlobeNewswire
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
From VALNEVA
Via GlobeNewswire
Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.
From VALNEVA
Via GlobeNewswire
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
From VALNEVA
Via GlobeNewswire
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed
From VALNEVA
Via GlobeNewswire
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
From VALNEVA
Via GlobeNewswire
U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ®
From VALNEVA
Via GlobeNewswire
Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance
From VALNEVA
Via GlobeNewswire
Valneva Announces Sale of Priority Review Voucher for $103 Million
From VALNEVA
Via GlobeNewswire
Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine
From VALNEVA
Via GlobeNewswire
Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Forum
From VALNEVA
Via GlobeNewswire
Valneva Provides Updated 2023 Financial Guidance
From VALNEVA
Via GlobeNewswire
Valneva Shareholders Approve EGM Resolutions Including the Transition to a Board of Directors
From VALNEVA
Via GlobeNewswire
Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15
From VALNEVA
Via GlobeNewswire
Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®
From VALNEVA
Via GlobeNewswire
EMA Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment
From VALNEVA
Via GlobeNewswire
Valneva Announces the Availability of Documentation for its Extraordinary General Meeting including Planned Changes to its Future Board of Directors
From VALNEVA
Via GlobeNewswire
Valneva Reports Positive Pivotal Phase 3 Immunogenicity Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate
From VALNEVA
Via GlobeNewswire
Valneva Announces U.S. FDA Approval of World’s First Chikungunya Vaccine, IXCHIQ®
From VALNEVA
Via GlobeNewswire
Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates
From VALNEVA
Via GlobeNewswire
Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference
From VALNEVA
Via GlobeNewswire
Valneva Submits Chikungunya Vaccine Marketing Application to EMA and Announces CHMP Accelerated Assessment
From VALNEVA
Via GlobeNewswire
Valneva to Present on Chikungunya at Several Leading Scientific Conferences
From VALNEVA
Via GlobeNewswire
Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32 Million
From VALNEVA
Via GlobeNewswire
Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates
From VALNEVA
Via GlobeNewswire
Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate
From VALNEVA
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today